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PURPOSE. Little is known regarding the therapeutic effect of carbonic anhydrase inhibitors
(CAIs) in the management of cystic macular lesions in children with X-linked juvenile
retinoschisis (XLRS) despite the fact that this disease often manifests during childhood.
Therefore, our goal was to determine the efficacy of CAIs in the treatment of cystic macular
lesions in children with XLRS.
METHODS. We used CAIs to treat cystic macular lesions in 18 eyes of nine children with XLRS.
We evaluated the therapeutic effect of CAI treatment with the best-corrected visual acuity and
foveal zone thickness (FZT) with spectral-domain optical coherence tomography. A reduction
of at least 22.4% in FZT was defined as objective evidence of response.
RESULTS. Five of nine (55.6%) XLRS patients showed a significant reduction of FZT in both eyes
over a median treatment interval of 6.8 months (range, 1–23). In four of five (80.0%) patients,
this reduction was already apparent after 1 month of treatment. An improvement of visual
acuity was observed in five eyes (27.8%) of three patients (33.3%). Six patients (66.6%)
reported minor side effects.
CONCLUSIONS. Treatment with CAIs decreased FZT in more than half of the children with XLRS.
This effect was observed within 1 month in the majority of patients. Carbonic anhydrase
inhibitor treatment restores retinal anatomy and may contribute to creating optimal
circumstances for gene therapy.
Keywords: carbonic anhydrase inhibitor, x-linked juvenile retinoschisis, cystoid macular
edema, foveal zone thickness, acetazolamide
X-linked juvenile retinoschisis (XLRS) is the leading cause ofhereditary juvenile macular degeneration in males, with an
estimated prevalence ranging from 1 in 5000 to 1 in 25,000.1
The onset of XLRS has been attributed to pathogenic mutations
in the retinoschisin gene (RS1) on the X chromosome, which
encodes a cell adhesion protein responsible for the architec-
tural integrity of the retina.2 Cystic macular lesions are the
hallmark features in the early stage of XLRS.3 The pathogenesis
of these cystic macular lesions is not entirely understood, but
they should not be confused with cystoid macular edema as the
normal appearance of the macula on fluorescein angiography in
patients with XLRS suggests that vascular leakage plays a minor
role, if any, in the pathogenesis of these cystic lesions.
Both oral and topical carbonic anhydrase inhibitors (CAIs)
have been used successfully in the management of cystic
lesions in macular dystrophies, including XLRS.4 The clinical
effect of CAIs is thought to be through their action on the
membrane-bound carbonic anhydrase receptors present in the
retinal pigment epithelium (RPE).5 Moreover, other carbonic
anhydrase receptors in different cells of the neural retina may
also play a role.6 Carbonic anhydrase inhibitors act both on
retinal and RPE cell function by acidifying the subretinal space,
decreasing the standing potential as well as raising retinal
adhesiveness, probably by increasing RPE fluid transport.5,7
The vast majority of previous studies investigated the effects
of CAI treatment in managing XLRS-associated cystic macular
lesions in adults.4,8–13 Few studies reported the effect of topical
CAIs in the management of cystic macular lesions in
children.13–16 To the best of our knowledge, only eight cases
of the effect of oral acetazolamide on cystic macular lesions in
children with XLRS have been reported in the literature.16–18
This is surprising since restoration of retinal function, albeit
temporarily, is more likely to occur in younger patients as
compared to adults, where structural alterations may prevent
visual improvement despite anatomical recovery.12 The aim of
this study was therefore to determine the efficacy of CAI
treatment in children with XLRS-associated cystic macular
lesions.
METHODS
Patients
This retrospective cohort study adhered to the tenets of the
Declaration of Helsinki, and informed consent was obtained
from all participants. We included nine XLRS patients (18 eyes)
with a mean age of 12.3 years (range, 6.4–16.6), who were
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treated with oral CAIs for cystic macular lesions between
March 2014 and March 2016 at the Institute of Ophthalmology
of the Radboud University Medical Center, Nijmegen (The
Netherlands). A 10th patient was excluded from the study
because he choose to discontinue treatment because of
paresthesias in the second week of treatment, as were patients
over 18 years of age and patients who did not take CAIs for at
least 4 weeks.
The diagnosis of XLRS was molecularly confirmed in four
out of nine patients. In the remaining five patients, no
molecular analysis was performed and the diagnosis of XLRS
was based on the combination of information regarding family
history, a decrease in visual acuity, a spoke-wheel pattern in the
macula on high-magnification ophthalmoscopy, and bilateral
foveoschisis on spectral-domain optical coherence tomography
(SD-OCT).
All nine patients were treated with oral acetazolamide with
a dose ranging from 125 mg two times a day to 250 mg three
times a day. In addition, six patients also used topical CAIs such
as brinzolamide (four patients) or dorzolamide (two patients)
(Table). Carbonic anhydrase inhibitor doses were mainly
dependent on the patients’ age, although adjustments were
made based on side effects and the effect on cystic macular
lesions seen on SD-OCT. The minimum effective CAI dose was
pursued.
Ophthalmic Data Collection
Information regarding best-corrected Snellen visual acuity and
retinal thickness measured on SD-OCT was collected from
baseline to the most recent visit during CAI treatment. For
statistical analysis, the best-corrected Snellen visual acuity was
converted into logarithm of the minimal angle of resolution
(logMAR) values. A change of 0.14 logMAR, corresponding
with a change of seven or more letters on the Early Treatment
Diabetic Retinopathy Study (ETDRS) chart, was considered
significant.11,12
Cross-sectional images were obtained using SD-OCT (Spec-
tralis HRAþOCT; Heidelberg Engineering, Heidelberg, Ger-
many). The foveal zone thickness (FZT) was calculated using
Heidelberg Eye Explorer software (version 1.8.6.0; Heidelberg
Engineering) in the central 1000-lm diameter circle (C1) of the
ETDRS grid.
The intervisit variability of SD-OCT measurements was
calculated using a previously described method based on the
FZT change in both eyes of four XLRS patients (no. 1, no. 6, no.
7, and no. 10, who was excluded from the rest of the study).
Baseline FZT was compared with the first preceding FZT up to
6 months prior to starting treatment, with a mean interval of
3.3 months (range, 2–6).12,19
The average difference was 10.1% and the average þ 2 SD
was 22.4%. Hence, in this study, a reduction of more than
22.4% in FZT was considered a significant response due to CAI
treatment.
During treatment, patients were advised to regularly eat
potassium-rich food to prevent possible hypokalemia caused
by the CAIs. Potassium levels were checked by the attending
ophthalmologist or general practitioner.
Statistical Analysis
Prognostic factors for the response to CAIs were analyzed with
a multivariable logistic regression analysis. Two-sided P values
of less than 0.05 were considered statistically significant. Data
were analyzed using SPSS Software (version 22.0; SPSS, Inc.,
Chicago, IL).
RESULTS
Five of nine (55.6%) XLRS patients showed a significant
reduction of FZT in both eyes over a median treatment interval
of 6.8 months (range, 1–23) (Table; Figs. 1, 2, 3). In four of five
(80.0%) patients, this significant reduction was already present
after 1 month of treatment. In the remaining patient (no. 5), no
information about FZT after 1 month of treatment was
available, but he already showed a FZT reduction of 10% and
6% after 12 days of treatment. The FZT reduction persisted
over a median treatment interval of 10.1 months (range, 7–16)
in eight eyes of the five patients. In two eyes, the right eye of
patient no. 2 and the left eye of patient no. 8, a rebound effect
occurred where the macular cysts returned to at least baseline
levels. This happened after dose reduction of oral acetazol-
amide from 125 mg three times a day to daily 250 mg with
sustained release in patient no. 2. In patient no. 8, the rebound
effect occurred after cessation of additional topical brinzola-
mide eight times a day. After restarting brinzolamide six times a
day, FZT again decreased significantly. Overall mean FZT
decreased from 409.1 lm at baseline to 332.8 lm at the most
recent visit during treatment (P ¼ 0.024). In the five patients
with a significant reduction, mean FZT decreased from 403.1
lm at baseline to 261.9 lm at the most recent visit during
FIGURE 1. Change in FZT over time. The solid black line indicates the mean FZT of the five XLRS patients with a significant reduction of FZT, and
the dotted black line indicates the mean FZT of the patients without a significant reduction. Vertical lines are the standard deviation of the mean
responder and mean nonresponder lines.
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treatment (P¼ 0.006). Age at baseline (P¼ 0.111) or mean FZT
at baseline (P ¼ 0.531) did not predict the response to CAIs.
Visual acuity improved significantly (‡0.14 logMAR) from
baseline value in at least one eye in three out of nine (33.3%)
XLRS patients. Two patients (22.2%) showed a significant
improvement of visual acuity in both eyes (Table; Fig. 4).
Overall, mean visual acuity at baseline (0.39 6 0.15 logMAR)
and mean visual acuity at the most recent visit (0.32 6 0.19
logMAR) were not statistically different (P ¼ 0.078). Only one
patient showed both a visual improvement and a significant
reduction in FZT at the most recent visit during CAI treatment.
Improvement of visual acuity was therefore not correlated with
a reduction in FZT as well as not correlated with patient age.
Six patients (66.6%) experienced minor side effects during
treatment, such as digital and/or perioral paresthesia (55.6%)
and fatigue (22.2%) (Table). In patient no. 9, the paresthesias
disappeared after switching from oral acetazolamide 250 mg
two times a day to oral acetazolamide with sustained release
250 mg daily.
DISCUSSION
We investigated the therapeutic effect of CAIs in the
management of cystic macular lesions in children with XLRS.
Five of nine patients showed a significant reduction of FZT in
both eyes that was observed within 1 month in the majority of
patients. Judged by the treatment effect in our patients, the
response to CAIs can be assessed after only 1 month in most
patients. This treatment response was quicker than the effect
described in XLRS patients by Apushkin and Fishman, though
they used only topical CAIs with notable lower doses.12 The
difference in treatment response might consequently be
explained by the dose differences between both studies as
dose dependency was previously described in patients with
XLRS or other retinal dystrophies who were treated with
CAIs.11,20,21 This is supported by the return of macular cysts
after reduction of the CAI dose in patients no. 2 and no. 8 that
may be, at least in part, dose dependent and not solely a
rebound effect.
In this study we defined FZT changes of more than 22.4% as
statistically significant. This percentage is slightly higher
compared to the 17.1% used in other studies.10–12 This
difference may be explained by the higher variation in
thickness in younger patients on which our calculation was
based. Not all patients could be included in the intervisit
percent difference calculations because of the lack of SD-OCT
scans made within 6 months prior to the baseline measure-
ment. By using 22.4% as the cutoff point, we might have
underestimated the CAI effect compared to other studies.
No prognostic factors for response to CAIs were found in
this study. Age at baseline and greater initial FZT did not affect
treatment response, although such influences were previously
described in patients with retinitis pigmentosa (RP).22
Improvement of visual acuity in at least one eye occurred in
three patients (33.3%). In accordance with previous studies,
improvement of visual acuity was not correlated with age nor
with reduction of central retinal thickness on OCT.10,19,23 To
our knowledge, the natural course of visual acuity in children
with XLRS has not been described previously. To be
comparable with studies performed in adults, we used 0.14
logMAR as cutoff point for improvement in visual acuity,
keeping in mind that the results may be over- or underesti-
mated.11,12
No patient discontinued CAI treatment due to the side
effects. However, one patient was excluded from the study
because he discontinued treatment due to paresthesias in the
second week of treatment. The disappearance of the side
effects in patient no. 9 can be caused by the switch to oral
acetazolamide with sustained release, but at the same time
patients’ total daily CAI dose was reduced. Consequently, we
cannot conclude that sustained release treatment shows fewer
side effects. Limitations of our study include its retrospective
nature, the inherent small cohort size of rare diseases, and the
variation in dosage of CAIs, partly by the selective use of
topical CAIs. Because of these limitations and the different
follow-up intervals, conclusions should be interpreted cau-
tiously.
Despite the side effects and the little improvement in visual
acuity, there may also be a long-term benefit in restoring
normal retinal anatomy. In patients with XLRS, treatment of the
FIGURE 2. Infrared and horizontal SD-OCT images (308) from the left eye of patient no. 7 showing the response to oral acetazolamide. Near-infrared
image with a projection of the ETDRS grid (a). The highlighted innermost circle of the grid was used to measure FZT. Spectral-domain optical
coherence tomography image at baseline (b), after 1 month of treatment (c) and after 13 months of treatment (d).
FIGURE 3. Horizontal SD-OCT images (308) from the right eye of
patient no. 8 showing the response to oral acetazolamide. Spectral-
domain optical coherence tomography image at baseline (a), after 1
month of treatment (b) and after 14 months of treatment (c).
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cystoid macular lesions may decrease the occurrence of later-
onset atrophic lesions and the associated visual loss.24
With upcoming treatments such as gene therapy, CAIs may
play a role in preserving and restoring retinal anatomy to create
optimal circumstances. Retinal pretreatment with CAIs shortly
before subretinal injection with transgene vectors may reduce
the risk of traumatic damage to the central retina caused by the
subretinal injection. The long-term benefits of CAI treatment,
especially in relation to the side effects, will have to be studied
further.
In conclusion, reduction of central retinal thickness
occurred in more than half of the children treated with CAIs,
but only three patients experienced visual improvement over a
median treatment interval of 6.8 months. Evaluation of
treatment effect is possible after only 1 month in the majority
of patients. Restoration of macular architecture with CAI
treatment may delay functional retinal loss and could be
important in the creation of more optimal circumstances for
gene therapy.
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